Gary A Ulaner1,2, Serge K Lyashchenko3,2, Christopher Riedl3,2, Shutian Ruan4, Pat B Zanzonico4, Diana Lake5,6, Komal Jhaveri5,6, Brian Zeglis7, Jason S Lewis3,2,8, Joseph A O'Donoghue4. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York ulanerg@mskcc.org. 2. Department of Radiology, Weill Cornell Medical College, New York, New York. 3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Medicine, Weill Cornell Medical College, New York, New York. 7. Department of Chemistry, Hunter College, New York, New York; and. 8. Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
In what we believe to be a first-in-human study, we evaluated the safety and dosimetry of 89Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)-targeted imaging in patients with HER2-positive breast cancer. Methods: Patients with HER2-positive breast cancer and evidence of distant metastases were enrolled in an institutional review board-approved prospective clinical trial. Pertuzumab was conjugated with deferoxamine and radiolabeled with 89Zr. Patients underwent PET/CT with 74 MBq of 89Zr-pertuzumab in a total antibody mass of 20-50 mg of pertuzumab. PET/CT, whole-body probe counts, and blood drawing were performed over 8 d to assess pharmacokinetics, biodistribution, and dosimetry. PET/CT images were evaluated for the ability to visualize HER2-positive metastases. Results: Six patients with HER2-positive metastatic breast cancer were enrolled and administered 89Zr-pertuzumab. No toxicities occurred. Dosimetry estimates from OLINDA demonstrated that the organs receiving the highest doses (mean ± SD) were the liver (1.75 ± 0.21 mGy/MBq), the kidneys (1.27 ± 0.28 mGy/MBq), and the heart wall (1.22 ± 0.16 mGy/MBq), with an average effective dose of 0.54 ± 0.07 mSv/MBq. PET/CT demonstrated optimal imaging 5-8 d after administration. 89Zr-pertuzumab was able to image multiple sites of malignancy and suggested that they were HER2-positive. In 2 patients with both known HER2-positive and HER2-negative primary breast cancers and brain metastases, 89Zr-pertuzumab PET/CT suggested that the brain metastases were HER2-positive. In 1 of the 2 patients, subsequent resection of a brain metastasis proved HER2-positive disease, confirming that the 89Zr-pertuzumab avidity was a true-positive result for HER2-positive malignancy. Conclusion: This first-in-human study demonstrated safety, dosimetry, biodistribution, and successful HER2-targeted imaging with 89Zr-pertuzumab PET/CT. Potential clinical applications include assessment of the HER2 status of lesions that may not be accessible to biopsy and assessment of HER2 heterogeneity.
In what we believe to be a first-in-human study, we evaluated the safety and dosimetry of 89Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)-targeted imaging in patients with HER2-positive breast cancer. Methods:Patients with HER2-positive breast cancer and evidence of distant metastases were enrolled in an institutional review board-approved prospective clinical trial. Pertuzumab was conjugated with deferoxamine and radiolabeled with 89Zr. Patients underwent PET/CT with 74 MBq of 89Zr-pertuzumab in a total antibody mass of 20-50 mg of pertuzumab. PET/CT, whole-body probe counts, and blood drawing were performed over 8 d to assess pharmacokinetics, biodistribution, and dosimetry. PET/CT images were evaluated for the ability to visualize HER2-positive metastases. Results: Six patients with HER2-positive metastatic breast cancer were enrolled and administered 89Zr-pertuzumab. No toxicities occurred. Dosimetry estimates from OLINDA demonstrated that the organs receiving the highest doses (mean ± SD) were the liver (1.75 ± 0.21 mGy/MBq), the kidneys (1.27 ± 0.28 mGy/MBq), and the heart wall (1.22 ± 0.16 mGy/MBq), with an average effective dose of 0.54 ± 0.07 mSv/MBq. PET/CT demonstrated optimal imaging 5-8 d after administration. 89Zr-pertuzumab was able to image multiple sites of malignancy and suggested that they were HER2-positive. In 2 patients with both known HER2-positive and HER2-negative primary breast cancers and brain metastases, 89Zr-pertuzumab PET/CT suggested that the brain metastases were HER2-positive. In 1 of the 2 patients, subsequent resection of a brain metastasis proved HER2-positive disease, confirming that the 89Zr-pertuzumab avidity was a true-positive result for HER2-positive malignancy. Conclusion: This first-in-human study demonstrated safety, dosimetry, biodistribution, and successful HER2-targeted imaging with 89Zr-pertuzumab PET/CT. Potential clinical applications include assessment of the HER2 status of lesions that may not be accessible to biopsy and assessment of HER2 heterogeneity.
Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Volkan Beylergil; Serge Lyashchenko; Shutian Ruan; Stephen B Solomon; Jeremy C Durack; Jorge A Carrasquillo; Robert A Lefkowitz; Mithat Gonen; Jason S Lewis; Jason P Holland; Sarah M Cheal; Victor E Reuter; Joseph R Osborne; Massimo F Loda; Peter M Smith-Jones; Wolfgang A Weber; Neil H Bander; Howard I Scher; Michael J Morris; Steven M Larson Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-21 Impact factor: 9.236
Authors: Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen Journal: Nat Protoc Date: 2010-03-25 Impact factor: 13.491
Authors: Spencer C Behr; Emma Bahroos; Randall A Hawkins; Lorenzo Nardo; Vahid Ravanfar; Emily V Capbarat; Youngho Seo Journal: Mol Imaging Biol Date: 2018-06 Impact factor: 3.488
Authors: Gary A Ulaner; David M Hyman; Dara S Ross; Adriana Corben; Sarat Chandarlapaty; Shari Goldfarb; Heather McArthur; Joseph P Erinjeri; Stephen B Solomon; Hartmuth Kolb; Serge K Lyashchenko; Jason S Lewis; Jorge A Carrasquillo Journal: J Nucl Med Date: 2016-05-05 Impact factor: 10.057
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Nolan Priedigkeit; Ryan J Hartmaier; Yijing Chen; Damir Vareslija; Ahmed Basudan; Rebecca J Watters; Roby Thomas; Jose P Leone; Peter C Lucas; Rohit Bhargava; Ronald L Hamilton; Juliann Chmielecki; Shannon L Puhalla; Nancy E Davidson; Steffi Oesterreich; Adam M Brufsky; Leonie Young; Adrian V Lee Journal: JAMA Oncol Date: 2017-05-01 Impact factor: 31.777
Authors: Adriana V F Massicano; Supum Lee; Bryant K Crenshaw; Tolulope A Aweda; Retta El Sayed; Ian Super; Ron Bose; Bernadette V Marquez-Nostra; Suzanne E Lapi Journal: Cancer Biother Radiopharm Date: 2019-01-24 Impact factor: 3.099
Authors: Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas Journal: Inorg Chem Date: 2020-11-10 Impact factor: 5.165
Authors: Joseph A O'Donoghue; Daniel C Danila; Neeta Pandit-Taskar; Volkan Beylergil; Sarah M Cheal; Stephen E Fleming; Josef J Fox; Shutian Ruan; Pat B Zanzonico; Govind Ragupathi; Serge K Lyashchenko; Simon P Williams; Howard I Scher; Bernard M Fine; John L Humm; Steven M Larson; Michael J Morris; Jorge A Carrasquillo Journal: Mol Pharm Date: 2019-05-31 Impact factor: 4.939
Authors: Jason S Lewis; Wolfgang A Weber; Christian Lohrmann; Eileen M O'Reilly; Joseph A O'Donoghue; Neeta Pandit-Taskar; Jorge A Carrasquillo; Serge K Lyashchenko; Shutian Ruan; Rebecca Teng; Wolfgang Scholz; Paul W Maffuid Journal: Clin Cancer Res Date: 2019-09-20 Impact factor: 12.531